To: axial who wrote (8647 ) 2/7/2002 2:29:02 AM From: Cal Gary Read Replies (2) | Respond to of 14101 Nice summary Jim! We need more shorters in DMX!!! Go Bashers Go!! Now that Shaw wave is back on line <ng> I can post again. How true:"Let's not forget that this unconscionable delay by HC is not just a waste of your investment dollars its also a wate of your tax dollars." If you happen to be American, then you can laugh at Canadians and Health Canada's track record. If you happen to be Canadian, then you can cry 'out loud.' I worked out the incredible odds at moving from preclinicals to market. 0.001 = 5 / 5000 or 1 in 1000 chance to making it to human clinical and 0.200 = 1 / 5 or 20% chance of human trials to FDA approval Yields === 0.0002 = 1 in 5,000 chance Better odds than the 649 lottery, but still a major win fall once the coveted FDA Approval Letter is in hand. Perhaps in 30 calendar days?!? So the odds, if you invested in DMX say 8 years ago for Pennsaid alone, was 1 in 5,000th chance end to end. From getting the compound into the lab, and out to the American market place. A major gamble in a HIGH RISK unproven junior Biotech. Yes, you were young(er) and .... So hats off to the really long timers, Bravo!! Stalwarts!! Where's Wayne?? Fast forward to February 2002. The odds against a plant approval is very low. The odds of getting FDA this calendar year is almost 100% So relatively new investors coming in at the eleventh hour at low odds, and relatively low prices, well ... , hats off to ya too! F.D.A.eh PS DMX ought to ask Health Canada to initiate a Phase V trials, so Canadian doctors can prescibe Pennsaid with special access provisions and DMX can gain some income on existing inventory. Business Development here I come!!<g> Phase I, II, III, IV, III ----> V Anyways, fore get HC for now, think F.D.A.eh!!